Eff orts to generate a vaccine against HIV have been disappointing, perhaps because of the unique tropism of HIV for CD4 + T cells. Infection with HIV is associated with rapidly acquired defects in cell cycle initiation in CD4 + cells and cytoxicity in CD8 + T cells ( 1 ) . Ultimately T cells become dysfunctional and fail to generate immune responses, leaving the patient vulnerable to opportunistic infections. The rapid onset of T cell dysfunction in HIV-infected patients invariably hinders early attempts to boost the immune system using vaccines and other interventions. Exhaustion of CD4 + and CD8 + T cells during HIV and other chronic viral infections has been associated with sustained expression of the inhibitory molecule PD-1, which results in inhibition of T cell expansion and cytokine production ( 2 -4 ) . However, as not all exhausted cells express PD-1, it is likely that other molecules may contribute to the exhaustion associated with HIV infection and other chronic viral infections. On p. 2763 of this issue, Jones et al. identify a novel molecular mechanism for T cell exhaustion mediated by the expression of TIM-3 ( 5 ).
The in TIM idation of T cells
The TIM family of genes, which consists of eight members in mice and three members in humans ( 6 ) , is located on chromosome 11 in mice and 5q33 in humans -genetic regions that have been associated with autoimmune and allergic diseases. TIM proteins are type 1 membrane proteins with a structurally conserved immunoglobulin variable (IgV) domain and mucin stalk that connects to an intracellular tail. TIM proteins were initially thought to be expressed specifically on the surface of diff erentiated effector T cells and to directly regulate their activity, but we now know that TIMs are also expressed on and regulate the function of antigen-presenting cells ( 7 ) . Crystal structures of the TIM molecules has revealed a unique, conserved structure with ligand-binding sites in the IgV domain ( 8 -10 ) .
TIM-3 was initially identifi ed as a molecule expressed on T helper (Th)-1, but not Th2, cells in mice ( 11 ) . Interaction between TIM-3 and its ligand galectin-9 inhibits Th1 responses ( 12 ) and induces peripheral tolerance ( 13, 14 ) . As in mice, TIM-3 is preferentially expressed on human Th1 cells, but is also expressed constitutively on macrophages and dendritic cells (DCs) ( 7 ) . Reduction of TIM-3 expression in T cells using small interfering RNA or blocking antibodies, for example, increases interferon (IFN)-␥ secretion by CD4 + T cells ( 15 ) , further supporting an inhibitory role of TIM-3 in human T cells.
Patient studies are consistent with this inhibitory function, as TIM-3 expression is defective on CD4 + T cells from patients with autoimmune diseases ( 15, 16 ) . Specifi cally, T cell clones isolated from the cerebrospinal fl uid of patients with multiple sclerosis (MS) express lower levels of TIM-3 and secrete higher levels of IFN ␥ compared with clones isolated from healthy control subjects ( 15 ) . CD4 + T cells from MS patients also show altered and delayed kinetics of TIM-3 upon activation, resulting in lower TIM-3 expression on circulating T cells and are therefore refractory to the blocking eff ects of TIM-3 -specifi c antibodies ( 16 ) .
TIM-1, by contrast, is predominantly expressed on Th2 cells and was fi rst identifi ed as the hepatitis A virus cellular receptor 1 ( 17 ) . A unique polymorphism in the mucin domain of TIM-1 regulates hepatitis A virus infection, and also affects immune responses and resistance to asthma, allergy, and atopy ( 18 ) .
TIM-3 in chronic virus infection
T cell exhaustion during HIV infection is accompanied by increased HIV replication and follows a characteristic pattern. T cells fi rst lose the ability to enter into cell cycle, to secrete IL-2, and to mediate cytotoxicity (2, 3) . Over time, the exhausted cells also lose the ability to secrete other cytokines, such as IFN-␥ and TNF (2, 3, 19) . Initial studies suggested that T cell dysfunction is mediated by sustained PD-1 expression on T cells. Upon activation, T cells upregulates several inhibitory molecules, including PD-1, which help turn off T cell responses and thus inhibit T cell expansion.
A functional role for PD-1/PD-L1 signaling in T cell dysfunction was demonstrated by studies of lymphocytic 
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suggest that TIM-3 may be an important therapeutic target that is distinct from PD-1 and may help reverse exhaustion in chronic viral infections. On CD4 + cells, TIM-3 is expressed only on terminally differentiated Th1 cells. Thus TIM-3 blockade would result in the expansion of only eff ector T cells. Therapeutic blockade of PD-1, on the other hand, would expand all T cells, because PD-1 is up-regulated on all activated T cells.
Open questions
Collectively, these data suggest that TIM-3 is a central regulator of T cell responses. In autoimmunity, loss of TIM-3 function leads to excessive expansion of autoreactive eff ector T cells. In chronic HIV infection, by contrast, sustained TIM-3 expression on CD4 + and CD8 + T cells leads to T cell exhaustion ( Fig. 1 ) .
As with any clinical observation, these results raise many questions. It is unclear, for example, whether HIV infection itself drives TIM-3 expression or whether CD4 + T cells expressing high levels of TIM-3 are preferentially infected with HIV or are exhausted in their attempt to clear the virus. How the engagement of TIM-3 by its ligand galectin-9 leads to the inability of T cells to enter into the cell cycle and secrete cytokines is also unknown. Since TIM-3 -galectin-9 interactions normally induce the death of terminally diff erentiated Th1 cells ( 12 ) , why aren ' t exhausted cells eliminated? And why, on the other hand, is TIM-3 expression reduced on Th1 cells in patients with autoimmune diseases such as MS?
Our recent discovery that TIM-3 is constitutively expressed by human DCs and monocytes revealed a potential role for TIM-3 in innate immune responses ( 7 ). It will be interesting to examine the function of TIM-3 on monocytes and DCs in patients with HIV infection, whether its expression changes during the course of infection, and whether TIM-3 aff ects the responsiveness of DCs to TLR and other innate signals.
The dysregulation of TIM-3 in patients with autoimmune disease and in chronic viral exhaustion highlight the therapeutic potential of targeting TIM-3 in the treatment of these diseases. Finally, these studies highlight the utility of investigating the same regulatory pathways in patients with HIV and autoimmunity to provide unique insights into the pathogenesis of these diseases.
